Scharton-Kersten T, Contursi C, Masumi A, Sher A, Ozato K
J Exp Med. 1997; 186(9):1523-34.
PMID: 9348310
PMC: 2199126.
DOI: 10.1084/jem.186.9.1523.
Yap G, Magram J, Sher A
J Exp Med. 1997; 185(7):1261-73.
PMID: 9104813
PMC: 2196248.
DOI: 10.1084/jem.185.7.1261.
Wilson C, Tsai V, Remington J
J Exp Med. 1980; 151(2):328-46.
PMID: 7356726
PMC: 2185778.
DOI: 10.1084/jem.151.2.328.
Locksley R, Wilson C, Klebanoff S
J Clin Invest. 1982; 69(5):1099-111.
PMID: 7068848
PMC: 370174.
DOI: 10.1172/jci110545.
Mack D, McLeod R
Antimicrob Agents Chemother. 1984; 26(1):26-30.
PMID: 6383209
PMC: 179910.
DOI: 10.1128/AAC.26.1.26.
Cellular defenses against Toxoplasma gondii in newborns.
Wilson C, Haas J
J Clin Invest. 1984; 73(6):1606-16.
PMID: 6327765
PMC: 437071.
DOI: 10.1172/JCI111367.
Oxidant-mediated damage of Leishmania donovani promastigotes.
Reiner N, Kazura J
Infect Immun. 1982; 36(3):1023-7.
PMID: 6284640
PMC: 551434.
DOI: 10.1128/iai.36.3.1023-1027.1982.
Role of lymphocyte blastogenesis to Toxoplasma gondii antigens in containment of chronic, latent T. gondii infection in humans.
McLeod R, Estes R
Clin Exp Immunol. 1985; 62(1):24-30.
PMID: 4064374
PMC: 1577415.
Activation of neonatal and adult human macrophages by alpha, beta, and gamma interferons.
Wilson C, Westall J
Infect Immun. 1985; 49(2):351-6.
PMID: 3926648
PMC: 262022.
DOI: 10.1128/iai.49.2.351-356.1985.
Enzyme immunoassay for evaluation of Toxoplasma gondii growth in tissue culture.
Merli A, Canessa A, Melioli G
J Clin Microbiol. 1985; 21(1):88-91.
PMID: 3881474
PMC: 271581.
DOI: 10.1128/jcm.21.1.88-91.1985.
Specific and nonspecific mediation of protective immunity to Toxoplasma gondii.
Reyes L, FRENKEL J
Infect Immun. 1987; 55(4):856-63.
PMID: 3557619
PMC: 260429.
DOI: 10.1128/iai.55.4.856-863.1987.
Prevention of peroral and congenital acquisition of Toxoplasma gondii by antibody and activated macrophages.
Eisenhauer P, Mack D, McLeod R
Infect Immun. 1988; 56(1):83-7.
PMID: 3335411
PMC: 259238.
DOI: 10.1128/iai.56.1.83-87.1988.
Enzyme immunoassay to assess effect of antimicrobial agents on Toxoplasma gondii in tissue culture.
Derouin F, Chastang C
Antimicrob Agents Chemother. 1988; 32(3):303-7.
PMID: 3284458
PMC: 172164.
DOI: 10.1128/AAC.32.3.303.
Microbicidal activity of monocyte derived macrophages in AIDS and related disorders.
Eales L, Moshtael O, Pinching A
Clin Exp Immunol. 1987; 67(2):227-35.
PMID: 3111759
PMC: 1542592.
Activation of murine macrophages and a bovine monocyte cell line by bovine lymphokines to kill the intracellular pathogens Eimeria bovis and Toxoplasma gondii.
Hughes H, Speer C, Kyle J, Dubey J
Infect Immun. 1987; 55(3):784-91.
PMID: 3102381
PMC: 260411.
DOI: 10.1128/iai.55.3.784-791.1987.
Semiautomated assessment of in vitro activity of potential antileishmanial drugs.
Berman J, Gallalee J
Antimicrob Agents Chemother. 1985; 28(6):723-6.
PMID: 3002244
PMC: 180316.
DOI: 10.1128/AAC.28.6.723.
In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii.
Chang H, Pechere J
Antimicrob Agents Chemother. 1988; 32(4):524-9.
PMID: 2837140
PMC: 172214.
DOI: 10.1128/AAC.32.4.524.
Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii.
Araujo F, Huskinson J, Remington J
Antimicrob Agents Chemother. 1991; 35(2):293-9.
PMID: 2024964
PMC: 244994.
DOI: 10.1128/AAC.35.2.293.